To evaluate the pharmacodynamic effects of the type I PRMT inhibitor, optimized IHC conditions for both ADM-R225-hnRNP-A1 and total hnRNP-A1 antibodies were employed on formalin-fixed tumor tissues from a mouse xenograft model using the Toledo human diffuse large B-cell lymphoma (DLBCL) cell line. Here, HNRNPA1 is linked to diffuse large B-cell lymphoma.